| Revision as of 09:01, 18 April 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit | Revision as of 11:25, 3 September 2011 edit undoBogBot (talk | contribs)Bots53,132 edits populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBotNext edit → | ||
| Line 1: | Line 1: | ||
| {{Drugbox | {{Drugbox | ||
| | verifiedrevid = 411550415 | | verifiedrevid = 411550415 | ||
| | IUPAC_name |
| IUPAC_name = N,N,2-Trimethyl-5-nitro-benzenesulfonamide | ||
| | image |
| image = BRL50481_structure.png | ||
| ⚫ | | CAS_number |
||
| <!--Clinical data--> | |||
| ⚫ | | ATC_prefix |
||
| | |
| tradename = | ||
| | |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | ||
| | |
| pregnancy_US = <!-- A / B / C / D / X --> | ||
| | pregnancy_category = | |||
| ⚫ | | C=9|H=12|N=2|O=4|S=1 | ||
| ⚫ | | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | ||
| ⚫ | | molecular_weight |
||
| ⚫ | | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | ||
| ⚫ | | smiles |
||
| ⚫ | | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | ||
| ⚫ | | bioavailability |
||
| ⚫ | | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | ||
| | protein_bound = | |||
| ⚫ | | legal_status = | ||
| ⚫ | | metabolism |
||
| ⚫ | | routes_of_administration = | ||
| ⚫ | | elimination_half-life = | ||
| ⚫ | | excretion |
||
| <!--Pharmacokinetic data--> | |||
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | |||
| ⚫ | | bioavailability = | ||
| | pregnancy_US = <!-- A / B / C / D / X --> | |||
| | |
| protein_bound = | ||
| ⚫ | | metabolism = | ||
| ⚫ | | legal_AU |
||
| ⚫ | | elimination_half-life = | ||
| ⚫ | | legal_CA |
||
| ⚫ | | excretion = | ||
| ⚫ | | legal_UK |
||
| ⚫ | | legal_US |
||
| <!--Identifiers--> | |||
| ⚫ | | legal_status |
||
| ⚫ | | CAS_number = 433695-36-4 | ||
| ⚫ | | routes_of_administration = | ||
| ⚫ | | ATC_prefix = | ||
| | ATC_suffix = | |||
| | PubChem = 2921148 | |||
| | DrugBank = | |||
| <!--Chemical data--> | |||
| ⚫ | | C=9 | H=12 | N=2 | O=4 | S=1 | ||
| ⚫ | | molecular_weight = 244.267 g/mol | ||
| ⚫ | | smiles = Cc1ccc(N(=O)=O)cc1S(=O)(=O)N(C)C | ||
| }} | }} | ||
Revision as of 11:25, 3 September 2011
Pharmaceutical compound | |
| Identifiers | |
|---|---|
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C9H12N2O4S |
| Molar mass | 244.267 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
| (verify) | |
BRL-50481 is a drug developed by GlaxoSmithKline which is the first compound that acts as a phosphodiesterase inhibitor selective for the PDE7 subtype. It has been shown to increase mineralisation activity in osteoblasts, suggesting a potential role for PDE7 inhibitors in the treatment of osteoporosis.
References
- Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA. Discovery of BRL 50481 , a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Molecular Pharmacology. 2004 Dec;66(6):1679-89. PMID 15371556
- Pekkinen M, Ahlström ME, Riehle U, Huttunen MM, Lamberg-Allardt CJ. Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts. Bone. 2008 Jul;43(1):84-91. PMID 18420479